These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32710666)

  • 1. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature.
    An X; Lei X; Huang R; Luo R; Li H; Xu F; Yuan Z; Wang S; de Nonneville A; Gonçalves A; Houvenaeghel G; Li J; Xue C; Shi Y
    Cancer; 2020 Aug; 126 Suppl 16():3837-3846. PubMed ID: 32710666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
    Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
    Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.
    Fasano GA; Bayard S; Chen Y; Varella L; Cigler T; Bensenhaver J; Simmons R; Swistel A; Marti J; Moore A; Andreopoulou E; Ng J; Brandmaier A; Formenti S; Ali H; Davis M; Newman L
    Breast Cancer Res Treat; 2022 Feb; 192(1):163-173. PubMed ID: 35022867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.
    Carbajal-Ochoa W; Bravo-Solarte DC; Bernal AM; Anampa JD
    Breast Cancer Res Treat; 2024 Jan; 203(2):257-269. PubMed ID: 37833449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of adjuvant chemotherapy on recurrence rate in T1abN0M0 triple-negative breast cancer: A meta-analysis.
    Yang Z; Chen Y; Liu X; Cui J; Hu Y; Wei W
    Cancer Treat Res Commun; 2020; 25():100211. PubMed ID: 33113437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis.
    Zhang J; Wang W; Wang J; Luo Y; Chen S; Ma F; Xu B; Fan Y
    J Oncol; 2020; 2020():8880727. PubMed ID: 33381180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis.
    Wu C; Huang O; Wu J; Shen K; Chen X; Zhu S
    Gland Surg; 2023 Oct; 12(10):1375-1386. PubMed ID: 38021197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are we overtreating stage I triple-negative breast cancer in Ontario? A population-based retrospective epidemiological analysis using the ICES database.
    Shum K; Hussein A; Hamm C
    Med Oncol; 2022 Sep; 39(12):228. PubMed ID: 36175693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
    Lim ST; Park CH; Kim SY; Nam SJ; Kang EY; Moon BI; Lee HJ; Jeon YW; Gwak H; Suh YJ
    PLoS One; 2018; 13(5):e0197523. PubMed ID: 29768496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
    Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Study of Treatment Patterns and Natural History of Patients with T1a/b N0 Triple-Negative Breast Cancers: A Single-Institution Experience.
    Liu L; Lewis N; Sun W; Whiting J; Hoover S; Costa RLB
    Oncology; 2023; 101(12):765-772. PubMed ID: 37527637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Use and Impact of Chemotherapy in Lymph Node-Negative, T1a Triple-Negative Breast Cancer.
    Bravo-Solarte DC; Zhang F; Anampa JD
    Clin Breast Cancer; 2023 Oct; 23(7):763-773.e6. PubMed ID: 37648557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
    Shen K; Yao L; Zhu J; Gu X; Wang J; Qian W; Zheng Z; Fu D; Wu S
    BMC Cancer; 2022 Aug; 22(1):863. PubMed ID: 35941565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.
    Roy S; Lakritz S; Schreiber AR; Molina E; Kabos P; Wood M; Elias A; Kondapalli L; Bradley CJ; Diamond JR
    Eur J Cancer; 2023 May; 185():69-82. PubMed ID: 36965330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors.
    Colonna SV; Higgins AK; Alvarez J; Saville BR; Lawrence J; Abramson VG
    Clin Breast Cancer; 2016 Jun; 16(3):223-31. PubMed ID: 26683741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
    Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
    Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
    Schreiber AR; Kagihara J; Eguchi M; Kabos P; Fisher CM; Meyer E; Molina E; Kondapalli L; Bradley CJ; Diamond JR
    Breast Cancer Res Treat; 2022 Jan; 191(2):389-399. PubMed ID: 34705147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
    Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
    JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy in small node-negative triple-negative breast cancer.
    Steenbruggen TG; van Werkhoven E; van Ramshorst MS; Dezentjé VO; Kok M; Linn SC; Siesling S; Sonke GS
    Eur J Cancer; 2020 Aug; 135():66-74. PubMed ID: 32554215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
    Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
    Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.